Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.49 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.49 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72839 | 0.92 | MTNR1A (0.49) | KMT2AMEN1LMNAPOLBMAPT | |
| SCHEMBL3228799 | 0.92 | KMT2A (0.57) | KMT2AMEN1LMNAPOLBMAPT | |
| SCHEMBL6839231 | 0.89 | KMT2A (0.50) | KMT2AMEN1LMNAPOLBMAPT | |
| SCHEMBL14026722 | 0.89 | KMT2A (0.41) | KMT2AMEN1LMNAPOLBMAPT | |
| SCHEMBL9205212 | 0.86 | ALDH1A1 (0.50) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL9204703 | 0.86 | L3MBTL1 (0.54) | KMT2AMEN1LMNAPOLBMAPT | |
| SCHEMBL5207376 | 0.85 | KMT2A (0.65) | KMT2AMEN1LMNAPOLBMAPT | |
| SCHEMBL7323723 | 0.84 | TDP1 (0.56) | KMT2AMEN1CYP1A2KDM4ETDP1 | |
| SCHEMBL29770500 | 0.84 | KMT2A (0.58) | KMT2ALMNAPOLBMTNR1AMTNR1B | |
| SCHEMBL628822 | 0.84 | KMT2A (0.58) | KMT2ALMNAPOLBMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112898208-B | Phenylpyrimidine amine antitumor compound and preparation method and application thereof | 中国医科大学 | 2023-06-20 | — | — | CN | claimed |
| CN-112778215-B | 2-methoxyphenoxypyrimidine antitumor compound and preparation method and application thereof | 中国医科大学 | 2023-06-20 | — | — | CN | claimed |
| CN-112898208-A | Phenyl pyrimidinamine antitumor compound and preparation method and application thereof | 中国医科大学 | 2021-06-04 | — | — | CN | claimed |
| CN-112778215-A | 2-methoxyphenoxy pyrimidine antitumor compound and preparation method and application thereof | 中国医科大学 | 2021-05-11 | — | — | CN | claimed |
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2331513-A1 | PROCESS FOR PREPARATION OF BOSENTAN | Cadila Healthcare Limited (IN) | 2011-06-15 | — | — | EP | claimed |
| EP-2240470-A2 | IMPROVED AND NOVEL PROCESS FOR THE PREPARATION OF BOSENTAN | MSN Laboratories Limited (IN) | 2010-10-20 | — | — | EP | claimed |
| WO-2010032261-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2010-03-25 | — | — | WO | claimed |
| WO-2009095933-A2 | IMPROVED AND NOVEL PROCESS FOR THE PREPARATION OF BOSENTAN | MSN LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | WO | claimed |
| EP-0841326-B1 | Process for the preparation of pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2001-05-16 | — | — | EP | claimed |
| CN-112898208-B | Phenylpyrimidine amine antitumor compound and preparation method and application thereof | 中国医科大学 | 2023-06-20 | — | — | CN | disclosed |
| CN-112778215-B | 2-methoxyphenoxypyrimidine antitumor compound and preparation method and application thereof | 中国医科大学 | 2023-06-20 | — | — | CN | disclosed |
| CN-112898208-A | Phenyl pyrimidinamine antitumor compound and preparation method and application thereof | 中国医科大学 | 2021-06-04 | — | — | CN | disclosed |
| CN-112778215-A | 2-methoxyphenoxy pyrimidine antitumor compound and preparation method and application thereof | 中国医科大学 | 2021-05-11 | — | — | CN | disclosed |
| US-20140275535-A1 | ACID ADDITION SALTS OF BOSENTAN | BIOCON LIMITED (IN) | 2014-09-18 | — | — | US | disclosed |
| EP-0743307-A1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1996-11-20 | — | — | EP | disclosed |
| US-5273993-A | Antiarthritic agents; osteoporosis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-12-28 | — | — | US | disclosed |
| US-5194446-A | Antiarthritic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-16 | — | — | US | disclosed |
| EP-0526708-A1 | Sulfonamide, preparation and use thereof as medicine and intermediate | F. HOFFMANN-LA ROCHE AG (CH) | 1993-02-10 | — | — | EP | disclosed |
| US-5025031-A | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants | A. H. ROBINS CO., INC. (US) | 1991-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CYP2D6, CYP3A5, QDPR | KMT2A 3992/4885MEN1 4576/4885LMNA 2768/4885 |
| US-20140275535-A1 | ACID ADDITION SALTS OF BOSENTAN | NCLN, EDNRB, EDNRA | KMT2A 4488/4885MEN1 1547/4885LMNA 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.